Printer Friendly

Rodman & Renshaw Healthcare Conference 2006 Presenter Profiles.

NEW YORK -- Rodman & Renshaw Healthcare Conference 2006 takes place 6-8 November at the New York Palace Hotel in New York. For in-depth information about the conference, visit http://www.rodmanandrenshaw.com/us06conference.

Below are profiles from Rodman & Renshaw Healthcare Conference 2006 exhibitors. Business Wire is the official news wire service for Rodman & Renshaw Healthcare Conference. Breaking news is available at http://www.tradeshownews.com, Business Wire's trade show, conference and event news resource.

Company: Ablynx nv

Investor Relations Contact: Dr. Edwin Moses, Chairman & CEO

Phone: +32-9-261-06-32

E-mail: edwin.moses@ablynx.com

Web: http://www.ablynx.com

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies[R], a novel class of antibody-derived therapeutic proteins, for a range of human diseases.

Ablynx's most advanced Nanobody[R] programs in acute thrombosis and inflammation show tremendous therapeutic potential in vivo and are approaching human clinical testing. The Company expects to initiate its first clinical trial in early 2007.

The company began operations in 2002 in Ghent, Belgium and currently employs ~80 staff.

Nanobodies[R] are unique and highly versatile single domain antibodies. Because of their small size, unique structure and unparalleled stability, Nanobodies[R] combine the beneficial features of conventional antibodies (such as affinity and selectivity) with the desirable properties of small molecules.

Company: Acceleron Pharma

Media Contact: Paul Kidwell, Kidwell PR, 617-296-3854

Investor Relations Contact: Steven Ertel, 617-576-2220, x234

Phone: 617-576-2220

Web: www.acceleronpharma.com

Acceleron Pharma, Inc. is a biopharmaceutical company developing regenerative therapeutics for the treatment of musculoskeletal, metabolic and cancer-related diseases. Acceleron was founded to take advantage of its unique insight on the Growth and Differentiation Factor (GDF) protein family. Acceleron is utilizing a novel approach to modulate the activity of various GDFs that control tissue growth thereby unleashing the body's inherent ability to rebuild and re-grow damaged or lost tissue. Acceleron is establishing itself as the premier company in the field of regenerative biotherapeutics with its lead program, ACE-011, is phase 1 trials for the treatment of bone loss

Company: Access Pharmaceuticals, Inc.

Ticker Symbol & Exchange: ACCP.OB

Media Contact: Rosemay Mazanet, Acting CEO

Investor Relations Contact: Donald C. Weinberger

Phone: 212-370-4500

E-mail: rosemary.mazanet@accesspharma.com

Web: www.accesspharma.com

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac[TM], currently in Phase II clinical testing of patients with ovarian cancer, and MuGard[TM], for the treatment of patients with mucositis.

The Company also has other advanced drug delivery technologies, including vitamin-mediated targeted delivery and oral drug delivery. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

Company: Acorda Therapeutics

Ticker Symbol & Exchange: ACOR

Investor Relations Contact: Erica Wishner

Phone: 914-347-4300 ext. 162

E-mail: ewishner@acorda.com

Web: www.acorda.com

Acorda Therapeutics[R] is a biotechnology company whose mission is to develop and market therapies to restore neurological function in people with spinal cord injury (SCI), multiple sclerosis (MS) and related conditions of the nervous system. Acorda's marketed products include Zanaflex CapsulesTM (tizanidine hydrochloride) and Zanaflex[R] (tizanidine hydrochloride) tablets. The Company announced positive results from its Phase 3 clinical trial of Fampridine-SR, the Company's lead product candidate, for the improvement of walking ability in people with MS in September 2006. Additionally, Acorda is developing multiple approaches to regeneration and repair of the spinal cord and brain.

Company: Active Biotech AB

Ticker Symbol & Exchange: ACTI.ST (SEK)

Investor Relations Contact: Cecilia Hofvander

Phone: +46-46-19-20-00

E-mail: Cecilia.hofvander@activebiotech.com

Web: www.activebiotech.com

Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication non-small cell lung cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex[R] for RA. In addition, the preclinical development of the I-3D project is being conducted in cooperation with Chelsea Therapeutics.

Company: Adeza Biomedical Corporation

Ticker Symbol & Exchange: Nasdaq: ADZA

Media Contact: Mark Fischer-Colbrie

Investor Relations Contact: Jody Cain

Phone: 408-745-0975

E-mail: ir@adeza.com

Web: www.adeza.com

Adeza designs, manufactures and markets innovative products for women's health. Adeza's initial focus is on reproductive healthcare using its proprietary technologies to predict preterm birth and assess infertility. Adeza's principal product is a patented diagnostic test, FullTerm, The Fetal Fibronectin Test, which utilizes a single-use, disposable cassette and is analyzed on Adeza's patented TLiIQ[R] System. This product is approved by the U.S. Food and Drug Administration (FDA) for use in assessing the risk of preterm birth. Adeza also markets and sells the E-tegrity[R] Test, an infertility-related test to assess receptivity of the uterus to embryo implantation in women with unexplained infertility. In May 2006, Adeza announced the submission of its New Drug Application (NDA) to the FDA for Gestiva, a long-acting form of a naturally occurring progesterone to prevent preterm birth in women with a history of preterm delivery and on October 20, 2006 received an approvable letter from the FDA.

Company: Adnexus Therapeutics

Media Contact: Katrine Bosley

Phone: 781-891-3745

E-mail: pr@adnexustx.com

Web: www.adnexustx.com

Adnexus is focused on generating vital medicines through the development and commercialization of its new protein therapeutic class, Adnectins.

Adnectins can address a broad range of diseases and surpass the limitations of other targeted therapeutics, such as antibodies. The intrinsic and predictable properties of the Adnectin product class align with the properties needed to make a successful drug, including high potency, specificity, stability, favorable half life and high yield production.

Adnexus' pipeline of Adnectin products spans several therapeutic areas. The portfolio is led by Angiocept (CT-322), which is in Phase 1 clinical development in oncology in the United States.

Company: Active Biotech AB

Ticker Symbol & Exchange: ACTI.ST (SEK)

Investor Relations Contact: Cecilia Hofvander

Phone: +46-46-19-20-00

E-mail: Cecilia.hofvander@activebiotech.com

Web: www.activebiotech.com

Active Biotech focuses on the research and development of pharmaceuticals. The Company has a strong R&D portfolio, with pipeline products focused on autoimmune/inflammatory diseases and cancer. Active Biotech's most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis; and ANYARA for use in cancer immunotherapy, with the primary indication of non-small cell lung cancer. Further key projects in clinical development include three orally administered compounds: TASQ for prostate cancer, 57-57 for SLE and RhuDex(r) for rheumatoid arthritis. Preclinical development of the I-3D project is being conducted with Chelsea Therapeutics.

Company: Advanced Life Sciences

Ticker Symbol & Exchange: ADLS

Media Contact: Edward P. Flavin

Investor Relations Contact: Dr. Paul Keough

Phone: 630-739-6744

E-mail: pkeough@advancedlifesciences.com

Web: www.advancedlifesciences.com

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a second generation ketolide antibiotic in late-stage clinical development for the treatment of respiratory tract infections.

Company: Advancis Pharmaceutical Corp.

Ticker Symbol & Exchange: NASDAQ: AVNC

Investor Relations Contact: Robert Bannon

Phone: 301-944-6710

E-mail: rbannon@advancispharm.com Web: www.advancispharm.com

Advancis is a pharmaceutical company focused on developing and commercializing anti-infective drug products that fulfill unmet medical needs in the treatment of infectious disease. Based on the Company's finding that bacteria exposed to antibiotics in sequential bursts, or pulses, are killed more efficiently than those exposed to standard treatment regimens, Advancis has developed a proprietary, once-a-day pulsatile delivery technology for antibiotics and other anti-infectives called PULSYS[TM]. The Company is currently marketing the Keflex brand of cephalexin, completed a successful Phase III trial for its pulsatile amoxicillin drug candidate, and is exploring pulsatile formulations for a range of other antibiotics.

Company: Ambrilia Biopharma Inc.

Ticker Symbol & Exchange: TSX: AMB (CN)

Investor Relations Contact: Julie M. Thibodeau

Phone: 514-751-2003 x235

E-mail: jthibodeau@ambrilia.com

Web: www.ambrilia.com

Ambrilia Biopharma Inc. (TSX:AMB) is a biopharmaceutical company developing innovative and proprietary early- to mid-stage therapeutics in the fields of oncology and infectious diseases. Ambrilia's product portfolio includes an anti-cancer therapeutic peptide, a novel anti-cancer therapy, two oncology specialty generics and promising anti-HIV treatments. Exclusive worldwide rights to Ambrilia's HIV Protease Inhibitor Program have been granted to Merck & Co., Inc. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France.

Company: Anadys Pharmaceuticals, Inc.

Ticker Symbol & Exchange: ANDS

Investor Relations Contact: Vince Reardon

Phone: 858-530-3600

E-mail: vreardon@anadyspharma.com Web: www.anadyspharma.com

Anadys Pharmaceuticals, Inc., is a biopharmaceutical company committed to advancing patient care by discovering, developing and commercializing novel small molecule medicines for the treatment of viral diseases and cancer. The Company has core expertise in structure-based drug design coupled with medicinal chemistry and Toll-Like Receptor-based small molecule therapeutics. Anadys' clinical development programs include ANA380 for the treatment of HBV, currently in mid-stage clinical development, and ANA975 for the treatment of HCV and HBV, which was suspended while in Phase Ib clinical trials due to pre-clinical toxicology observations in animals. The IND covering ANA975 is currently on full clinical hold; however, a new pre-clinical study has been initiated as a step toward the objective to resume the ANA975 clinical program. Overall, Anadys' therapeutic platform is designed to advance a strong and continual pipeline of drug candidates into the clinic.

Company: AngioDynamics, Inc.

Ticker Symbol & Exchange: NASDAQ:ANGO

Investor Relations Contact: Kim Sutton Golodetz / Lisa Lindberg

Phone: 212-838-3777

E-mail: kgolodetz@lhai.com / llindberg@lhai.com

Web: www.angiodynamics.com

AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease. AngioDynamics, Inc. designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. The Company's diverse product line includes angiographic products and accessories, dialysis products, vascular access products, PTA products, drainage products, thrombolytic products and venous products.

Company: Anika Therapeutics, Inc.

Ticker Symbol & Exchange: (NASDAQ:ANIK)

Investor Relations Contact: Kevin Quinlan

Phone: 781-932-6616

E-mail: kquinlan@anikatherapeutics.com

Web: www.anikatherapeutics.com

Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. Our products are based on hyaluronic acid (HA), a naturally occurring biocompatible polymer found throughout the body that enhances joint function and coats, protects, cushions and lubricates soft tissues.

Anika's current commercial products focus on two areas: ophthalmic surgery and osteoarthritis conditions. Active new product development initiatives include novel formulations for a family of cosmetic tissue augmentation therapies, and next generation products for treatment of osteoarthritis.

A public company since 1993, Anika is headquartered in Woburn, Mass.

Company: Arbios Systems, Inc.

Ticker Symbol & Exchange: ABOS: OTC BB

Media Contact: MacDougall Biomedical Communications

Investor Relations Contact: Walter Ogier, President & CEO

Phone: 781-839-7293

E-mail: wogier@arbios.com

Web: http://www.arbios.com

Arbios Systems, Inc. is a publicly traded medical device and cell therapy company based in Massachusetts and California that is engaged in the discovery, acquisition and development of proprietary liver assist devices and new technologies useful in the treatment and diagnosis of liver failure. Arbios' lead products in development include the SEPET[TM] Liver Assist Device, a novel blood purification therapy currently being tested in a feasibility clinical trial, and the HepatAssist[TM] Cell-Based Liver Support System, combining liver cell therapy and device-based detoxification, currently in Phase III clinical development. Arbios believes there are no effective proprietary therapies yet available for liver failure, and patients experience prolonged episodes in intensive care units with excessive mortality.

Company: Aspyra, Inc.

Booth/Stand: Holmes II 4th Floor

Ticker Symbol & Exchange: APY (AMEX)

Media Contact: The Wall Street Group, Inc.

Investor Relations Contact: Ronald Stabiner, Vice President

Phone: 212-888-4848

E-mail: sbesbeck@aspyra.com

Web: www.aspyra.com

Aspyra is a global provider of clinical and diagnostic information solutions for the healthcare industry, with over 35 years of industry experience, specializing in enterprise-wide systems for hospitals, multi-specialty clinics, clinical laboratories, imaging departments and centers, orthopedic practices and pharmacies. Our highly scalable products may be installed as standalone or integrated to provide a single-vendor solution. Aspyra product offerings include Laboratory, Anatomic, Radiology and Pharmacy Information Systems, Picture Archiving Communication Systems and Clinical Image Management Systems. Aspyra's products provide cost effective, robust application features to manage comprehensive clinical activities throughout most sectors of the healthcare provider marketplace.

Company: Avigen, Inc.

Ticker Symbol & Exchange: AVGN - Nasdaq

Investor Relations Contact: Michael Coffee

Phone: 510-748-7150

E-mail: ir@avigen.com

Web: www.avigen.com

Avigen, Inc. is a biopharmaceutical company focused on unique small molecule therapeutics and biologics to treat serious, chronic neurological disorders, including neuropathic pain and neuromuscular spasm and spasticity. For press releases and other corporate information, visit our website at www.avigen.com.

Company: Bio-Bridge Science, Inc.

Ticker Symbol & Exchange: BGES (OTCBB)

Investor Relations Contact: Chris Young

Phone: 630-928-0869

E-mail: investor@bio-bridge-science.com

Web: www.bio-bridge-science.com

Bio-Bridge Science is a development stage biotechnology company engaged in the commercial development of vaccines for the prevention and treatment of human diseases. The company is currently developing and commercializing an oral HIV vaccine to prevent and treat infection by HIV-1. The oral HIV vaccine pre-clinical trials have been completed. The company holds the exclusive license for the oral HIV vaccine technology with respect to China, the United States, and Japan. The company plans to develop vaccines to treat and prevent cervical cancer and colon cancer using the same technology in the near future.

Company: BioMarin Pharmaceutical, Inc.

Ticker Symbol & Exchange: Nasdaq:BMRN & SWX:BMRN

Media Contact: Susan Ferris

Investor Relations Contact: Eugenia Shen

Phone: 415-506-6570

E-mail: eshen@bmrn.com

Web: www.BMRN.com

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio is comprised of two approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation. Investigational product candidates include Phenoptin(TM) (sapropterin dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU), and 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of poorly controlled hypertension.

Company: BioMimetic Therapeutics, Inc.

Ticker Symbol & Exchange: BMTI / NASDAQ

Investor Relations Contact: Kearstin Patterson

Phone: 615-236-4419

E-mail: kpatterson@biomimetics.com

Web: www.biomimetics.com

BioMimetic Therapeutics is developing and commercializing innovative drug-device combination products to promote the healing of musculoskeletal injuries and diseases, including orthopedic, periodontal, spine and sports injury applications. BioMimetic received marketing approval from the FDA for its first product, GEM 21S[R], as a grafting material for bone and periodontal regeneration. Additionally, the Company has clinical trials ongoing for orthopedic bone healing indications. BMTI's biologically-enhanced therapeutic device product and product candidates are designed to provide new treatment options to improve the quality of life for millions of patients suffering injuries or deterioration of the bones, cartilage, ligaments and tendons.

Company: Biophan Technologies, Inc.

Ticker Symbol & Exchange: OTC:BIPH and FSE:BTN

Media Contact: Carolyn Hotchkiss, 585-214-2441

Investor Relations Contact: Jim Blackman, 713-256-0369

Phone: 585-214-2441

E-mail: info@biophan.com and techsales@biophan.com

Web: www.biophan.com

Biophan develops and markets cutting-edge technologies for the medical device industry. The Company's goals are to develop biomedical devices capable of safely working with magnetic resonance imaging (MRI) systems and to provide other technologies that improve the delivery of healthcare. These technologies enable implants such as pacemakers and stents, and interventional surgical devices including guidewires and catheters, to be safely and effectively imaged under MRI.

Biophan also has a minority interest in MYOTECH, LLC to help develop and commercialize the MYO-VAD[TM], a novel, MRI-compatible cardiac recovery system that has significant potential for improving the treatment of many forms of heart disease.

Company: BioSante Pharmaceuticals, Inc.

Ticker Symbol & Exchange: Amex: BPA

Media Contact: Stephen M. Simes

Investor Relations Contact: Phillip Doenenberg

Phone: 847-478-0500, ext. 100

E-mail: donenber@biosantepharma.com

Web: www.biosantepharma.com

BioSante is developing a pipeline of hormone therapy products to treat both men and women. BioSante's lead products include Bio-E-Gel (transdermal estradiol gel) for the treatment of women with menopausal symptoms and LibiGel[R] (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD). A Bio-E-Gel NDA was submitted to the FDA in the first quarter 2006. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including avian flu and biodefense vaccines, and drug delivery systems.

Company: Cardiome Pharma Corp.

Ticker Symbol & Exchange: COM (TSX), CRME (NASDAQ)

Media Contact: Fahreen Bhimani

Investor Relations Contact: Peter Hofman

Phone: 604-677-6905

E-mail: phofman@cardiome.com

Web: www.cardiome.com

Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two clinical drug programs focused on atrial arrhythmia, and a pre-clinical program directed at improving cardiovascular function.

Vernakalant (iv) is the intravenous formulation of an investigational drug being evaluated for the acute conversion of atrial fibrillation (AF). Positive results from two pivotal Phase 3 trials for vernakalant (iv) in December 2004 and September 2005. Cardiome and its co-development partner Astellas Pharma US, Inc. are working toward re-submitting a New Drug Application for vernakalant (iv).

Vernakalant (oral) is being investigated as a chronic-use oral drug for the maintenance of normal heart rhythm following termination of AF. Cardiome announced positive results from a Phase 2a pilot study for vernakalant (oral) in September 2006.

Company: Ceragenix Pharmaceuticals

Ticker Symbol & Exchange: OTCBB:CGXP

Media Contact: Robert Stanislaro

Investor Relations Contact: Evan Smith

Phone: 212-850-5657

E-mail: Robert.stanislaro@fd.com

Web: www.ceragenix.com

Ceragenix Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops and commercializes novel anti-infective drugs based on its proprietary class of compounds, Ceragenins[TM]. Active against a broad range of gram positive and negative bacteria, these agents are being developed as anti-infective medical device coatings (Ceracides[TM]) and as therapeutics for antibiotic-resistant organisms.

Ceragenix further owns exclusive rights to Barrier Repair Technology for the treatment of dermatological disorders including atopic dermatitis, neonatal skin disorders and others. Ceragenix's patented Barrier Repair Technology, invented by Dr. Peter Elias, is the platform for the development of two prescription topical creams--EpiCeram(R) and NeoCeram(R).

Company: Chemokine Therapeutics Inc

Ticker Symbol & Exchange: OTCBB: CHKT

Investor Relations Contact: Don Evans

Phone: 604-822-0305

E-mail: devans@chemokine.net

Web: www.chemokine.net

Chemokine Therapeutics Corp. (TSX:CTI) (OTCBB:CHKT) is a product-focused biotechnology company developing drugs in the field of chemokines. Chemokines are a class of signaling proteins which play a critical role in the growth, differentiation and maturation of cells necessary for fighting infection as well as tissue repair and regeneration. Chemokines also have an important role in cancer metastasis and growth. Established in 1998, Chemokine Therapeutics has become a leader in research in the field of chemokines and has several products in various stages of development.

Presentation: Wednesday, November 8 @ 2:50 p.m.

Company: Clearant, Inc.

Ticker Symbol & Exchange: OTCBB:CLRI

Investor Relations Contact: Jon Garfield, CFO

Phone: 310-479-4570

E-mail: jgarfield@clearant.com

Web: www.clearant.com

Clearant, Inc. is a leader in pathogen inactivation for biological products. Clearant has developed the patent-protected Clearant Process, which substantially reduces all types of bacteria and viruses in biological products while maintaining the functionality of the underlying tissue implant or protein. The Company began to distribute directly to surgeons, hospitals and clinics Clearant Process sterile implants in June 2006; in addition, Clearant continues to license the Clearant Process and provides its patented sterilization services to tissue banks and other biological products manufacturers. As of the end of 1Q 2006, Clearant had 10 license and service agreements with tissue banks. To date more than 8,000 patients have been successfully implanted with Clearant Process sterile implants supplied by one of the Company's licensed partners.

Presentation: 11/06/06 @ 12:25 p.m.

Company: Cleveland BioLabs, Inc.

Ticker Symbol & Exchange: Nasdaq:CBLI

Investor Relations Contact: Rachel Levine

Phone: 646-284-9439

E-mail: rlevine@hfgcg.com

Web: www.cbiolabs.com

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has two late-stage compounds in development: Curaxin CBLC102 for hormone refractory prostate cancer, which will commence a Phase II trial in Fall 2006; and Protectan CBLB502, a radioprotectant, which may benefit from an accelerated FDA approval process for military and defense applications. The Company has strategic partnerships with the Cleveland Clinic Foundation, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute. To learn more about Cleveland BioLabs Inc., please visit the company's website at http://www.cbiolabs.com.

Company: Columbia Laboratories, Inc.

Ticker Symbol & Exchange: Nasdaq:CBRX

Media Contact: Tina Posterli, Rx Communications Group

Investor Relations Contact: Melody Carey, Rx Communications Group

Phone: 917-322-2571

E-mail: mcarey@rxir.com

Web: www.columbialabs.com

Columbia Laboratories is a specialty pharmaceutical company dedicated to the development and commercialization of reproductive healthcare and endocrinology products that use its novel bioadhesive drug delivery technology. Columbia markets PROCHIEVE[R] 8% (progesterone gel) for progesterone supplementation as part of an Assisted Reproductive Technology treatment for infertile women with progesterone deficiency and PROCHIEVE[R] 4% (progesterone gel) for the treatment of secondary amenorrhea. The Company also markets STRIANT[R] (testosterone buccal system) for the treatment of hypogonadism in men. The Company recently completed enrollment in a large-scale pivotal Phase III study to evaluate the possible utility of PROCHIEVE[R] 8% (progesterone gel) in the prevention of recurrent preterm birth, for which there is currently no FDA-approved treatment. This randomized, double-blind, placebo-controlled trial involves 669 patients at more than 60 centers globally. The Company's additional research and development programs include a vaginally-administered lidocaine product to treat dysmenorrhea. For more information, please visit www.columbialabs.com.

Company: CombinatoRx, Incorporated

Ticker Symbol & Exchange: CRXX

Investor Relations Contact: Gina Nugent

Phone: 1-617-301-7099

E-mail: gnugent@combinatorx.com

Web: www.combinatorx.com

CombinatoRx, Incorporated (CRXX) is pioneering the new field of synergistic combination pharmaceuticals and has a broad product portfolio in phase 2 clinical development. Going beyond traditional combinations, CombinatoRx creates product candidates with novel mechanisms of action striking at the biological complexities of human disease. The lead programs in the CombinatoRx portfolio are advancing into later stage clinical trials based on the strength of multiple positive phase 2a results. This portfolio is internally generated from the CombinatoRx proprietary drug discovery technology which provides a renewable and previously untapped source of novel drug candidates. The Company was founded in 2000 and is located in Cambridge, Mass. To learn more about CombinatoRx please visit www.combinatorx.com.

Company: Compugen Ltd.

Ticker Symbol & Exchange: CGEN

Media Contact: Tsipi Haitovsky

Investor Relations Contact: Nurit Benjamini

Phone: +972-3-7658585

E-mail: tsipi@cgen.com

Web: www.cgen.com

Compugen's mission is to be the world leader in the discovery and licensing of product candidates to the drug and diagnostic industry. The Company's powerful discovery engines enable the predictive discovery of numerous potential therapeutics and diagnostic biomarkers. This capability results from the Company's decade-long pioneering efforts in the deeper understanding of important biological phenomena at the molecular level through the incorporation of ideas and methods from mathematics, computer science and physics into biology, chemistry and medicine. To date, Compugen's product discovery efforts and its initial discovery engines have focused mainly within the areas of cancer, immune-related and cardiovascular diseases.

Company: CompuMed, Inc.

Ticker Symbol & Exchange: CMPD.OB

Investor Relations Contact: Michael Porter, 212-564-4700

Phone: 310-258-5000

E-mail: invest@compumed.net

Web: www.compumed.net

CompuMed is positioned to become the world's leading provider of remote image analysis in cardiology and radiology. CompuMed has years of experience in telecardiology interpretation and over-reading services plus the analysis of radiological images for osteoporosis. The Company's products are FDA cleared and approved for reimbursements by Medicare. CompuMed has developed an innovative approach to the delivery of cardiology and radiology services by operating a centralized, state-of-the-art reading center featuring proprietary workflow technologies and analytics. The Company intends to significantly expand its service offerings in cardiology as well as into related teleradiology sectors for a wide spectrum of diseases including musculoskeletal (bone), cardiovascular, and metabolic diseases.

Company: Critical Therapeutics, Inc.

Ticker Symbol & Exchange: CRTX:NASDAQ

Investor Relations Contact: Linda S. Lennox

Phone: 781-402-5708

E-mail: llennox@crtx.com

Web: www.crtx.com

Critical Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of products for respiratory, inflammatory and critical care diseases. The Company owns worldwide rights to the asthma drug ZYFLO[R] (zileuton tablets), as well as the controlled-release and intravenous formulations of zileuton. ZYFLO is the only 5-lipoxygenase inhibitor approved for marketing by the U.S. Food and Drug Administration (FDA). The Company submitted the new drug application to the FDA for the twice daily, controlled-release formulation of zileuton in July 2006 and expects to launch the drug in the second half of 2007, pending regulatory approval.

Company: CytoDyn, Inc.

Ticker Symbol & Exchange: OTCBB:CYDY

Media Contact: Stacia Roum

Investor Relations Contact: Corinne Allen

Phone: 505-988-5520

E-mail: mail@cytodyn.com

Web: www.cytodyn.com

Emerging growth biotech company developing first-in-class products to treat and to prevent serious diseases, inluding Cytolin (immune restoration for HIV/AIDS, Phase I/II), DNA based pre-vaccines for avian and mammalian influenza (the flu) (pre-clinical), and Formaxycin, a dermatologic product intended to clear pre-cancerous lesions of the skin (in formulation). Strategic alliances include several universities and Utek Corp. Traunch financing and small dilution have characterized the Company's development-stage activities.

Company: Cytogen Corporation

Ticker Symbol & Exchange: NASDAQ:CYTO

Investor Relations Contact: Susan M. Mesco

Phone: 609-750-8213

E-mail: smesco@cytogen.com

Web: www.cytogen.com

Cytogen is a biopharmaceutical company dedicated to advancing the care of cancer patients by acquiring, developing, and commercializing innovative pharmaceutical products. The Company's specialty sales force currently markets QUADRAMET[R], PROSTASCINT[R], and SOLTAMOX[TM]. QUADRAMET is approved for the treatment of pain in patients whose cancer has spread to the bone; PROSTASCINT is a PSMA-targeting monoclonal antibody-based agent to image the extent and spread of prostate cancer; and Soltamox, is the first liquid hormonal therapy approved in the U.S. for the treatment of breast cancer in adjuvant and metastatic settings. The Company is also developing a third-generation radiolabeled antibody to treat prostate cancer. Cytogen's product-focused strategy focuses on sustainable growth through clinical, commercial and strategic initiatives.

Company: Cytokinetics, Inc.

Ticker Symbol & Exchange: CYTK

Investor Relations Contact: Jodi Goldstein

Phone: 650-624-3086

E-mail: jgoldstein@cytokinetics.com Web: www.cytokinetics.com

Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that specifically target the cytoskeleton. Cytokinetics' focus on the cytoskeleton enables it to develop novel and potentially safer and more effective classes of drugs directed at treatments for cancer, cardiovascular disease and other diseases. Ispinesib (SB-715992), SB-743921 and GSK-923295 are being developed under the strategic alliance with GlaxoSmithKline for the treatment of cancer and other diseases. Cytokinetics' unpartnered cardiovascular disease program is the second program to leverage the company's expertise in cytoskeletal pharmacology.

Company: diaDexus, Inc.

Media Contact: Barbara Sullivan, 714-374-6174

Investor Relations Contact: Patrick Plewman, 650-246-6400

Phone: 650-246-6400

E-mail: bsullivan@sullivanpr.com

Web: www.diaDexus.com

diaDexus, Inc., a privately held biotechnology company based in South San Francisco, Calif., is focused on the discovery, development, and commercialization of clinically valuable, patent-protected diagnostic products. The company's PLAC[R] test has been cleared for marketing by the Food and Drug Administration as an aid in predicting risk for coronary heart disease and ischemic stroke associated with atherosclerosis. The test measures lipoprotein-associated phospholipase A2 (Lp-PLA2), a cardiovascular-specific inflammatory enzyme associated with unstable, rupture-prone plaqueCothe leading cause of cardiovascular events. diaDexus also is developing a pipeline of novel cancer diagnostic tests. For more information, visit www.plactest.com or www.diaDexus.com.

Company: Domantis Ltd.

Investor Relations Contact: Gregory D. Perry

Phone: 781-250-2833 ext. 31

E-mail: gregory.perry@domantis.com

Web: www.domantis.com

Domantis Ltd. is a biopharmaceutical company developing human domain antibody (dAb) therapeutics to treat many diseases including potential best in class therapies for rheumatoid arthritis (RA), asthma, chronic obstructive pulmonary disease (COPD) and multiple myeloma (MM). The company has 15 proprietary therapeutic programs and nine partnered programs and several of these programs will enter clinical trials in 2007. Since its inception, Domantis has raised a total of $83 million from a global syndicate of investors including Novo Nordisk and 3i and expects to sign a significant alliance this year to develop and commercialize dAb therapies.

Company: DOR BioPharma, Inc.

Ticker Symbol & Exchange: DORB:OTCBB

Media Contact: Keith Thornton

Investor Relations Contact: Evan Myrianthopoulos

Phone: 786-425-3848

E-mail: emyrian@dorbiopharma.com

Web: www.dorbiopharma.com

DOR BioPharma, Inc. is a biopharmaceutical company developing products for life-threatening side effects of cancer treatments, serious gastrointestinal diseases, and bioterrorism. Our lead product, orBec[R] (oral beclomethasone dipropionate), is a potent, locally-acting corticosteroid being developed for the treatment of gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of bone marrow transplantation. DOR BioPharma has recently filed a New Drug Application (NDA) with the FDA for orBec[R] for the treatment of GI GVHD. orBec[R] may also have applications in treating other gastrointestinal disorders characterized by severe inflammation.

Through our BioDefense Division, we are developing biomedical countermeasures pursuant to the recently enacted Project BioShield Act of 2004. Our biodefense products in development are recombinant subunit vaccines designed to protect against the lethal effects of exposure to ricin toxin and botulinum toxin. Our ricin toxin vaccine, RiVaxTM, has successfully completed a Phase I clinical trial in normal volunteers.

For further information regarding DOR BioPharma, please visit the Company's website located at http://www.dorbiopharma.com.

Company: Dyadic International, Inc.

Ticker Symbol & Exchange: DIL:AMEX

Investor Relations Contact: Sasha Bondar

Phone: 561-743-8333

E-mail: sbondar@dyadic.com

Web: www.dyadic.com

Dyadic develops, manufactures and sells biological products using proprietary fungal strains to produce enzymes and other biomaterials. Dyadic produces enzymes that convert agricultural products (e.g. corn) and waste products (e.g. wheat straw) into fermentable sugars used in the production of traditional and cellulosic ethanol and other products now derived from petroleum. Dyadic's technology also is being developed to facilitate the discovery, development and large-scale production of human antibodies and other therapeutic proteins. Dyadic currently sells 45 liquid and dry enzyme products to 200 industrial customers worldwide for the textile, pulp & paper, animal feed, alcohol, starch, and food and beverage industries.

Company: Dynogen Pharmaceuticals, Inc.

Investor Relations Contact: Heather Savelle

Phone: 781-839-5149

E-mail: hsavelle@dynogen.com

Web: www.dynogen.com

Dynogen is a clinical-stage company developing a portfolio of more effective treatments for gastrointestinal and genitourinary disorders. The Company is focused on capturing value in attractive and untapped markets in disease areas that severely impair a patient's quality of life, such as irritable bowel syndrome, gastroesophageal reflux disease and overactive bladder. The Company leverages its development expertise to identify promising clinical compounds and rapidly advance them towards registration. Dynogen currently has multiple double-blind, placebo-controlled Phase 2 studies underway. www.dynogen.com.

Company: Emisphere Technologies, Inc.

Ticker Symbol & Exchange: EMIS / Nasdaq

Media Contact: Dan Budwick / BMC Communications

Investor Relations Contact: Stewart Siskind / Emisphere Technologies

Phone: 914.347.2220

E-mail: Info@Emisphere.com

Web: www.Emisphere.com

Emisphere Technologies, Inc. specializes in the oral delivery of therapeutic molecules that are not currently deliverable by oral means or have low oral absorption. Emisphere's broad based oral drug delivery technology platform, known as eligen[R] technology, is based on the use of proprietary, synthetic chemical compounds, known as EMISPHERE[R] delivery agents, or "carriers". These molecules facilitate or enable the transport of active therapeutic molecules across biological membranes such as those of the gastrointestinal tract.

Company: Endocyte, Inc.

Investor Relations Contact: Vickey Buskirk

Phone: 765-463-7175

E-mail: vbuskirk@endocyte.com

Web: www.endocyte.com

Endocyte is working to introduce a new generation of therapies with enhanced targeting capabilities to treat different forms of cancer and inflammatory disease. Based on a proprietary advanced receptor-targeting technology, the company's research and development focus includes both drug therapies and diagnostic agents. Endocyte currently has three products in clinical trials and two more positioned to enter the clinic in the next 12 months. Endocyte maintains full commercial rights to four of our five pipeline drugs. In January 2006 Endocyte entered into a licensing agreement with Bristol-Myers Squibb for the development of targeted epothilone-based chemotherapeutic agents. Endocyte also has a strong patent position, with 30 issued patents and 131 pending applications.

Backed by a strong investment group, Endocyte has raised $62 million in capital.

Company: Endologix, Inc.

Ticker Symbol & Exchange: Nasdaq:ELGX

Investor Relations Contact: Jody Cain, Lippert/Heilshorn & Assoc.

Phone: 310-691-7100

E-mail: jcain@lhai.com

Web: www.endologix.com

Endologix, Inc. develops and manufactures minimally invasive treatments for vascular diseases. Endologix's Powerlink System is an endoluminal stent graft (ELG) for treating abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it the thirteenth leading cause of death in the U.S. Presentation: 11/7/06 @ 8:50 a.m.

Company: EntreMed, Inc.

Ticker Symbol & Exchange: ENMD

Investor Relations Contact: Ginny Dunn

Phone: 240-864-2643

E-mail: ginnyd@entremed.com

Web: www.entremed.com

EntreMed, Inc. is a clinical-stage pharmaceutical company focused on developing next generation multi-mechanism oncology and anti-inflammatory drugs that target disease cells directly and the blood vessels that nourish them. EntreMed is focused on developing drugs that are safe and convenient, and provide the potential for improved patient outcomes. Panzem[R] (2-methoxyestradiol or 2ME2), one of the Company's lead drug candidates, is currently in Phase 2 clinical trials for cancer, as well as in preclinical development for rheumatoid arthritis. MKC-1, a novel cell cycle inhibitor acquired through the acquisition of Miikana Therapeutics, is also in Phase 2 clinical trials for cancer. In May 2006, the Company commenced clinical studies with its third clinical-stage compound, ENMD-1198, in patients with advanced cancer.

Company: EpiCept Corporation

Ticker Symbol & Exchange: Nasdaq Global Market:EPCT

Media Contact: Francesca DeVellis, 617-577-8110

Investor Relations Contact: Robert W. Cook, CFO

Phone: 201-894-8980

E-mail: mail@epicept.com

Web: www.epicept.com

EpiCept is focused on developing novel, effective and safe prescription pain products delivering drugs to a target area by using a topical delivery approach as opposed to systemic or transdermal modes, together with a late-stage cancer product in European registration and biopharmaceutical discovery capabilities for apoptosis inducers designed to address unmet medical needs in oncology. The Company's products address significant market opportunities. EpiCept has also established strategic alliances with Adolor, Endo, and Myriad Genetics for commercialization activities. EpiCept is headquartered in Englewood Cliffs, N.J., with a discovery research facility in San Diego, Calif., and a subsidiary in Munich, Germany.

Company: Epigenomics AG

Ticker Symbol & Exchange: ECX, Prime Standard Frankfurt

Investor Relations Contact: Achim Plum

Phone: +49-30-24345-368

E-mail: ir@epigenomics.com

Web: www.epigenomics.com

Epigenomics, a molecular diagnostic company with a focus on the development of novel products for cancer, is presenting at the Rodman & Renshaw Healthcare Conference on November 8, 9.10am EST in New York.

Using DNA methylation markers, Epigenomics' tests can potentially diagnose disease at an early stage and help guide physicians to select an appropriate therapy. Epigenomics collaborates with Roche Diagnostics on the development of several diagnostic products for the early detection of colon, prostate and breast cancer. Epigenomics also works with Qiagen (pre-analytics) and Affymetrix (diagnostic platform) as strategic partners for its molecular pathology products.

Company: Exact Sciences Corporation

Ticker Symbol & Exchange: EXAS

Investor Relations Contact: Jeffrey R. Luber, SVP, CFO and GC

Phone: 508-683-1211

E-mail: jluber@exactsciences.com

Web: www.exactsciences.com

EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Laboratory Corporation of America Holdings (LabCorp) offers the first of these tests, "PreGen-Plus[TM]," based upon technology licensed from EXACT. PreGen-Plus is used for screening for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than 20 years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies will help enable detection of colorectal cancer so that more people can be effectively treated.

Company: E-Z-EM, Inc.

Ticker Symbol & Exchange: NASDAQ:EZEM

Investor Relations Contact: Kim Sutton Golodetz / Anne Marie Fields

Phone: 212-838-3777

E-mail: kgolodetz@lhai.com / afields@lhai.com

Web: www.ezem.com

E-Z-EM is a leading manufacturer of contrast agents for gastrointestinal radiology. The Company recently introduced VoLumen[R] the next generation low density barium sulfate suspension for use as an oral contrast in Multidetector CT (MDCT) and Positron Emission Tomography (PET/CT) studies. The Company also offers Empower[R] - the only family of CT injectors on the market with patented EDA[TM] technology that can help detect contrast extravasation - and offers a complete product set for the virtual colonoscopy practitioner. The Company is also the exclusive world-wide manufacturer and marketer of RSDL for first-responder organizations and military services.

Company: Favrille, Inc.

Ticker Symbol & Exchange: Nasdaq:FVRL

Investor Relations Contact: Pete De Spain

Phone: 858-526-2426

E-mail: pdespain@favrille.com

Web: www.favrille.com

Favrille is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.

Company: GammaCan International Inc

Ticker Symbol & Exchange: OTCBB:GCAN

Investor Relations Contact: Yaron Cherny

Phone: 972-3-738-2616

E-mail: ycherny@GammaCan.com

Web: www.GammaCan.com

GammaCan (OTCBB: GCAN), is an Israeli/American company that develops immunotherapies to treat cancer. We are currently planning to initiate phase I/II trials of VitiGam under an IND. VitGam is our second generation IgG product to treat patients with stage III & IV melanoma. VitiGam is manufactured from plasma of donors with Vitiligo, a benign skin condition. Using animal models, we demonstrated that Vitiligo-derived IgG displays potent anti-melanoma activity. GCAN 101 our first generation IgG is in phase II testing in solid tumors. GammaCan owns two issued U.S. patents that cover IgG in cancer and has several patent applications pending.

Company: Genetic Technologies Limited

Ticker Symbol & Exchange: GENE - NASDAQ Global Market

Investor Relations Contact: Mr. Everard Hunder

Phone: +61-3-9415-1135

E-mail: everard.hunder@gtg.com.au Web: www.gtg.com.au

Genetic Technologies is a leading Australian life science company specializing in the fields of genetics and genomics.

Testing:

The company provides a range of genetic tests to customers in Australia and overseas, covering humans, animals and plants. The company is Australia's largest provider of paternity testing.

Licensing:

The company holds more than 150 patents, the best known relating to 'noncoding DNA', which have been granted in more than 20 countries.

Research:

RareCellect[R]: The non-invasive isolation of foetal cells for use in genetic testing

ImmunAid: The use of the immune system to control cancer

Pathogens: Discovery of antiparasitic compounds

Genomic Matching Technique: Simpler, cheaper and more informative genetic tests for human diseases

Addictive States: Identifying the causes of cocaine addiction

Company: Gentium S.p.A.

Ticker Symbol & Exchange: NASDAQ:GENT

Investor Relations Contact: Kim Sutton Golodetz / Anne Marie Fields

Phone: 212-838-3777

E-mail: kgolodetz@lhai.com / afields@lhai.com

Web: www.gentium.com

Gentium S.p.A. is a biopharmaceutical company located in Villa Guardia (Como), Italy that is focused on the research, discovery and development of drugs derived from DNA extracted from natural sources, and drugs that are synthetic derivatives, to treat and prevent a variety of vascular diseases and conditions related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate in the U.S., is an investigational drug that has been granted Orphan Drug status by the U.S. FDA to treat Severe VOD and Fast Track designation for the treatment of Severe VOD in recipients of stem cell transplants.

Company: GTC Biotherapeutics

Ticker Symbol & Exchange: GTCB - NASDAQ

Investor Relations Contact: Thomas Newberry

Phone: 508-370-5374

E-mail: thomas.newberry@gtc-bio.com

Web: www.gtc-bio.com

GTC Biotherapeutics develops, produces and commercializes therapeutic proteins through transgenic animal technology. We obtained the first approval of a transgenically derived product anywhere in the world. ATryn[R], our recombinant form of human antithrombin, was approved by the European Commission in August 2006 for use in patients with a hereditary antithrombin deficiency undergoing surgical procedures.

GTC established a strategic collaboration with LFB Biotechnologies of France in October 2006 to jointly develop recombinant forms of human plasma proteins and monoclonal antibodies. The first program of the collaboration will be to develop recombinant human factor VIIa as a potential treatment for hemophilia with inhibitors. LFB has also committed to invest $25 million in GTC.

Company: Halozyme Therapeutics, Inc.

Ticker Symbol & Exchange: AMEX: HTI

Investor Relations Contact: David Ramsay, CFO

Phone: 858-794-8889

E-mail: dramsay@halozyme.com

Web: www.halozyme.com

Halozyme is a biopharmaceutical company developing and commercializing recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets. The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases. Halozyme's recombinant human enzymes may replace current animal slaughterhouse-derived extracts that carry potential risks of animal pathogen transmission and immunogenicity. The company has received FDA approval for two products: Cumulase[R], the first and only recombinant human hyaluronidase for cumulus removal in the IVF process; and Hylenex for use as an adjuvant to increase the absorption and dispersion of other injected drugs. The versatility of the first enzyme, rHuPH20, enables Halozyme to develop the product as a medical device, drug enhancement agent and therapeutic drug. Presentation: 11/06/06 @ 12:05 p.m.

Company: Hana Biosciences, Inc.

Ticker Symbol & Exchange: HNAB - NASDAQ

Investor Relations Contact: Remy Bernarda

Phone: 650-228-2769

E-mail: remy.bernarda@hanabiosciences.com

Web: www.hanabiosciences.com

Hana Biosciences, Inc. is a South San Francisco, Calif.-based biopharmaceutical company that acquires, develops and commercializes innovative products to advance cancer care. Hana is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding the pipeline by being the partner of choice, and nurturing a unique company culture. Hana's pipeline currently has seven products, including one filed NDA for Zensana[TM] (Ondansetron HCI) Oral Spray for the prevention of chemotherapy, radiation and post-operative associated nausea and vomiting. If approved by the FDA, the company intends to commercially launch Zensana[TM] in U.S. in 2007.

Company: Helicos BioSciences Corporation

Media Contact: Sally Bain, 781-487-4647

Investor Relations Contact: Louise Mawhinney, Vice President & CFO

Phone: 617-264-1870

E-mail: lmawhinney@helicosbio.com

Web: www.helicosbio.com

Helicos BioSciences Corporation began operations in February 2004, and has raised $67 million to date from a top-tier investment consortium. Helicos's unique genetic analysis technology platform known as tSMS[TM], true single molecule sequencing, is based on the research of Dr. Stephen Quake of Stanford University. The technology, currently under development, is designed to sequence individual molecules of DNA or RNA at an unprecedented level of throughput, low cost, scalability and accuracy while allowing the comparison of genes and genomes from thousands of individuals. The Company commenced early-access collaborations in 2006 and plans to launch its first commercial systems in 2007.

Company: HemoSense, Inc.

Ticker Symbol & Exchange: Amex:HEM

Investor Relations Contact: Don Markley

Phone: 310-691-7100

E-mail: dmarkley@lhai.com

Web: www.hemosense.com

HemoSense develops, manufactures and sells easy-to-use, handheld blood coagulation monitoring systems for point-of-care (POC) testing and self-testing of patients taking the leading anti-clotting drug Coumadin (warfarin), an oral blood-thinning agent given to patients to prevent potentially lethal blood clots. Like diabetics on insulin, patients on warfarin require frequent, accurate data to help manage their health. The Company's INRatio System[R] consists of a small, portable monitor and disposable test strips that provide a quick and accurate measurement of blood-clotting time, known as a PT/INR value. Accurate and routine measurements of PT/INR are necessary for the safe and effective management of the patient's warfarin dosing. INRatio is sold in the United States and internationally.

Company: Hollis-Eden Pharmaceuticals, Inc.

Ticker Symbol & Exchange: NASDAQ:HEPH

Investor Relations Contact: Scott Rieger

Phone: 858-587-9333 ext. 407

E-mail: srieger@holliseden.com

Web: www.holliseden.com

Hollis-Eden Pharmaceuticals is developing a proprietary new class of small molecule compounds that are metabolic conversion products or synthetic analogs of adrenal steroid hormones. These compounds have been demonstrated in humans to possess several properties with potential therapeutic benefit - they regulate innate and adaptive immunity, reduce nonproductive inflammation and stimulate cell proliferation. The Company's lead product candidate, NEUMUNE, is entering late-stage development for the treatment of Acute Radiation Syndrome, a life-threatening condition resulting from exposure to radiation following a nuclear or radiological incident. Hollis-Eden also is profiling second-generation compounds for potential clinical development in a broad spectrum of therapeutic categories.

Company: ImVisioN Therapeutics. Inc.

Investor Relations Contact: Dr. Martin Steiner

Phone: +49-511-538-896-76

E-mail: m.Steiner@imvision-therapeutics.com

Web: www.imvision-therapeutics.com

ImVisioN Therapeutics Inc. is a private biotechnology company incorporated in Nevada, USA, with a heritage in Switzerland and Germany. The Company focuses on the development of allergy treatments that use its proprietary intralymphatic immunotherapy (ILIT) technology. Allergy treatments using ILIT are safer, more efficacious and more convenient to use than conventional allergy therapies and the technology has recently achieved clinical proof of concept. The Company has a lead product, shortly to enter the clinic, focused on cat dander allergy and programs addressing birch pollen and house dust mite allergy. ImVisioN plans to address further allergy targets using its proprietary technologies.

Company: Innnovative Biosensors, Inc. (IBI)

Media Contact: Dashaun Dorsey

Phone: 301-405-8425

E-mail: info@innovativebiosensors.com

Web: www.innovativebiosensors.com

Innovative Biosensors, Inc. (IBI) develops and manufactures rapid testing systems for the detection of pathogens that are of interest to human clinical diagnostics and biodefense.

Company: InSite Vision Incorporated

Ticker Symbol & Exchange: ISV AMEX

Investor Relations Contact: Ashton Partners, Barry Hutton

Phone: 888-857-7839

E-mail: bhutton@ashtonpartners.com

Web: www.insitevision.com

InSite Vision is an ophthalmic company focused on developing therapies that treat ocular infections, glaucoma and retinal diseases. InSite Vision's lead product AzaSite[TM] targets eye infections. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic formulated with DuraSite, InSite Vision's patented drug-delivery vehicle, which offers the benefit of a low-dosing regimen, attractive to both the eye-care patient and physician. If its NDA is approved by the FDA, InSite Vision currently expects AzaSite to be commercially launched in the U.S., while seeking to expand this "technology platform" to include additional product candidates and indications for the worldwide market.

Company: International Stem Cell Corporation

Media Contact: Nevena Orbach, The Orbach Company Inc.

Investor Relations Contact: Jeff Krstich, CEO

Phone: 760-940-6383

E-mail: jkrstich@intlstemcell.com

Web: www.internationalstemcell.com

With research and product development facilities in Oceanside, Calif., Walkersville, Md., and Moscow, Russia, ISC's mission is to bring to market therapeutic-grade human cells, derived from unfertilized human eggs, to treat human degenerative diseases using embryonic stem cell technologies. ISC's initial focus is on the treatment of diabetes, liver and retinal diseases. The company also has developed, produces and markets serum-free growth media and reagents essential to the process of creating and differentiating stem cells into therapeutic products. Contact: Jeff Krstich, CEO at jkrstich@intlstemcell.com or 760-940-6383. Visit ISC's website at www.internationalstemcell.com.

Company: Iomai Corp.

Ticker Symbol & Exchange: IOMAI (Nasdaq)

Media Contact: Brian Reid

Investor Relations Contact: Daryl Messinger

Phone: 301-556-4500

E-mail: rwilson@iomai.com

Web: www.iomai.com

Iomai Corporation develops potent and safe vaccines and other immune stimulants, delivered through simple adhesive patches. The company has pioneered a technology called transcutaneous immunization, which taps into the skin's immune function by targeting specialized skin cells that carry vaccines and immune stimulants directly to the immune system.

The company is running clinical trials for an influenza vaccine patch and a patch to enhance the efficacy of traditional flu vaccination in the elderly and is in preclinical development for a dose-sparing patch to be used an influenza pandemic. Finally, a patch-based vaccine for travelers' diarrhea is in Phase 2 testing.

Company: KAI Pharmaceuticals, Inc.

Investor Relations Contact: Kristine Ball

Phone: 650-244-1100

E-mail: kball@kaipharma.com

Web: www.kaipharma.com

KAI Pharmaceuticals is a biology-based, product-driven biopharmaceutical company developing a new class of therapeutics that selectively target enzymes within the protein kinase C (PKC) family, with an initial focus in acute cardiovascular disease, angiogenesis, pain and inflammation.

KAI recently completed a Phase I/II clinical study of KAI-9803, a delta PKC inhibitor, to prevent reperfusion injury in patients undergoing angioplasty following acute myocardial infarction (AMI). The FDA has granted KAI-9803 Fast Track designation. KAI-1455, the Company's development candidate for cytoprotection during ischemic surgical procedures, is expected to enter clinical trials in early 2007.

Company: Lipid Sciences, Inc.

Ticker Symbol & Exchange: LIPD, Nasdaq

Investor Relations Contact: Deborah S. Lorenz

Phone: 925-249-4031

E-mail: dlorenz@lipidsciences.com

Web: www.lipidsciences.com

Lipid Sciences is a development-stage biotechnology company engaged in researching and developing products and processes to treat major medical indications in which lipids, or fat components, play a key role. The HDL Therapy platform (HDL Selective Delipidation and HDL mimetic peptides) focuses on reversing plaque build-up in the vascular system and coronary arteries thereby reducing acute coronary events. The Viral Immunotherapy platform focuses on removing lipid coatings from lipid-enveloped viruses, through delipidation technology, to stimulate the body's immune system to fight disease. Conditions that could be impacted by this technology include: HIV, Hepatitis B and C, West Nile, SARS, influenza, and a broad range of animal health applications.

Company: LipoSonix, Inc.

Media Contact: Cam Pollock, Director of Marketing

Investor Relations Contact: Jens U. Quistgaard, President and CEO

Phone: 425-368-2010

E-mail: info@liposonix.com

Web: www.liposonix.com

LipoSonix, Inc. is a Seattle-based medical device company developing innovative products for non-invasive body sculpting. The technology utilizes high-intensity ultrasound, focused through the skin, to break down fatty tissue without harming skin or underlying tissues and organs. The body's natural healing mechanisms then clear the damaged tissue, resulting in a volume reduction. The targeted effect is similar to that of liposuction surgery, but the procedure is totally non-invasive. The company has completed a series of pilot clinical studies and expects to enter a pivotal US clinical trial in early 2007.

Company: MacroChem Corporation

Ticker Symbol & Exchange: OTCBB:MACM

Investor Relations Contact: The Investor Relations Group - Jordan Silverstein

Phone: 212-825-3210

E-mail: bpatriacca@macrochem.com

Web: www.macrochem.com

MacroChem (OTCBB:MACM.OB) is a specialty pharmaceutical company that develops and seeks to commercialize pharmaceutical products. Currently, our portfolio of product candidates is based on our proprietary drug delivery technologies: SEPA[R], MacroDerm(TM), and DermaPass(TM). Our lead product candidate, EcoNail(TM), a topically applied SEPA-based econazole lacquer for the treatment of onychomycosis, a condition commonly known as nail fungus, is currently in a Phase 2 clinical trial. Our other clinical stage product candidate, Opterone[R], a topically applied SEPA-based testosterone cream designed to treat male hypogonadism, is ready to advance to a Phase 2 clinical trial for which we are seeking a partner.

Company: Manhattan Pharmaceuticals, Inc.

Ticker Symbol & Exchange: AMEX:MHA

Investor Relations Contact: Michelle Carroll

Phone: 212-582-3950

E-mail: mcarroll@manhattanpharma.com

Web: www.manhattanpharma.com

Manhattan Pharmaceuticals, Inc. (AMEX:MHA), a development stage pharmaceutical company, acquires and develops proprietary prescription drugs for large, underserved patient populations. In view of the worldwide obesity epidemic, the company is developing Oleoyl-estrone (OE), an orally administered novel therapeutic for the treatment of obesity. To meet the needs of other major, underserved medical markets Manhattan Pharmaceuticals is also developing PTH (1-34), a peptide believed to be a regulator of epidermal cell growth, for psoriasis and Propofol Lingual Spray, a convenient, proprietary lingual spray formulation of propofol, the world's best-selling general anesthetic, as a sedative-hypnotic for use during diagnostic and therapeutic procedures.

Company: MaxCyte, Inc.

Media Contact: Douglas Doerfler

Investor Relations Contact: Ron Holtz

Phone: 301-944-1700

E-mail: info@maxcyte.com

Web: www.maxcyte.com

MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. The Company's proprietary ex vivo cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility, which are fundamental to successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers: one in Phase I/II clinical trials and several preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology.

Company: MediGene AG

Ticker Symbol & Exchange: MDGDE

Media Contact: Julia Hofmann and Dr. Georg DEnges

Investor Relations Contact: Dr. Michael Nettersheim

Phone: +49-89-8565-2900

E-mail: medigene@medigene.com

Web: www.medigene.com

MediGene AG is a publicly quoted biotechnology company, with its headquarters in Martinsried near Munich, Germany, and subsidiaries in Oxford, U.K., and San Diego, USA. MediGene is the first German biotech company with a drug on the market. A New Drug Application for a second drug has been filed. In addition, several drug candidates are currently in clinical development. MediGene also possesses innovative platform technologies. The company's core competence lies in research and development of novel approaches in anti cancer and autoimmune therapies. Thus MediGene focuses on indications of high medical need and great economic opportunities.

Company: METHYLGENE INC.

Ticker Symbol & Exchange: TSX:MYG

Investor Relations Contact: Rhonda Chiger

Phone: 1-917-322-2569

E-mail: rchiger@rxir.com

Web: www.methylgene.com

MethylGene is a publicly-traded biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics in cancer. Two cancer product candidates are currently in clinical trials: MGCD0103, partnered with Pharmion Corporation and Taiho Pharmaceutical Co., Ltd., and MG98, partnered with MGI Pharma, Inc. MethylGene has an exclusive license agreement with Merck & Co. for the development and commercialization of small molecule beta-lactamase inhibitors to overcome antibiotic resistance. MethylGene has partnered its non-oncology HDAC program for neurodegenerative diseases with EnVivo Pharmaceuticals. MethylGene has a portfolio of preclinical programs for its multi-targeted kinase and histone deacetylase (HDAC) inhibitors for both oncology and non-oncology indications, and continues to seek partnering opportunities in these areas.

Company: Micrus Endovascular Corportation

Ticker Symbol & Exchange: Nasdaq:MEND

Media Contact: John Kilcoyne

Investor Relations Contact: Jody Cain

Phone: 310-691-7100

E-mail: jcain@lhai.com

Web: www.micruscorp.com

Micrus develops, manufactures and markets medical devices for the treatment of cerebral vascular diseases. Micrus products are used by interventional neuroradiologists and neurosurgeons primarily to treat cerebral aneurysms responsible for hemorrhagic stroke, a significant cause of death worldwide. Micrus' product line enables physicians to gain access to the brain in a minimally invasive manner through the vessels of the circulatory system. Micrus' proprietary, three-dimensional microcoils automatically deploy within the aneurysm, forming a scaffold that conforms to a wide diversity of aneurysm shapes and sizes. Micrus also sells accessory devices used in conjunction with its microcoils. Micrus markets it products through a direct sales force in North America and parts of Europe, and through distributors serving major markets in Japan, Europe, Latin America, Asia and the Middle East.

Company: MorphoSys AG

Ticker Symbol & Exchange: FSE:MOR (Germany)

Media Contact: Mario Brkulj

Investor Relations Contact: Dr. Claudia Gutjahr-LEser

Phone: +49 89 89927 122

E-mail: investors@morphosys.com

Web: www.morphosys.com

MorphoSys is one of the world's leading biotechnology companies focusing on fully human antibodies. With its proprietary technologies, MorphoSys is developing not only the next generation of therapeutic antibodies, but also antibodies for research and diagnostics purposes. HuCAL[R] (Human Combinatorial Antibody Library) is a very powerful technology for the rapid and automated production of specific antibodies. The most distinctive feature of the library is the capability to optimize fully human antibodies to pre-defined specifications, allowing MorphoSys researchers and their partners to "Engineer the Medicines of Tomorrow." MorphoSys's goal is to establish HuCAL as the technology of choice for antibody generation in all market sectors.

Company: Neurochem Inc.

Ticker Symbol & Exchange: NASDAQ:NRMX; TSX:NRM

Investor Relations Contact: Dr. Lise HE[umlaut]bert

Phone: 450-680-4500

E-mail: ir@neurochem.com

Web: www.neurochem.com

Neurochem Inc. is a dynamic biopharmaceutical company focused on the development and commercialization of innovative therapeutics to address critical unmet medical needs. Eprodisate (KIACTA[TM]; formerly FIBRILLEX[TM]) is currently being developed for the treatment of AA amyloidosis, and is under regulatory review for marketing approval by the U.S. Food and Drug Administration and European Medicines Agency. Tramiprosate (ALZHEMED[TM]), for the treatment of Alzheimer's disease, is currently in Phase III clinical trials in both North America and Europe and tramiprosate (CEREBRIL[TM]), for the prevention of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial.

Company: NeurogesX, Inc.

Media Contact: Stephen Ghiglieri

Investor Relations Contact: Jody Cain

Phone: 650-508-2116

E-mail: sghiglieri@neurogesx.com

Web: www.NeurogesX.com

NeurogesX is a privately held specialty pharmaceutical company focused on the development of novel treatments for the management of neuropathic pain. Initial development efforts have been focused on formulation and clinical testing of Transacin[TM], a topical, physician administered patch containing a high concentration of trans-capsaicin, a synthetic form of the naturally occurring TRPV1 agonist-based treatment for chronic pain, in the areas of painful HIV-associated neuropathy (HIV-AN), post-herpetic neuralgia (PHN) and painful diabetic neuropathy (PDN). Currently, the company has successfully completed a Phase 3 study in HIV-AN and has three Phase 3 studies ongoing in both HIV-AN and PHN. NeurogesX intends to file for marketing approval in Europe in the first half of 2007 and plans to file an NDA in the United States in 2008.

Company: Neuromed Pharmaceuticals

Media Contact: Julie Jang - Manager, Communications

Investor Relations Contact: Bruce Colwill - Chief Financial Officer

Phone: 604-909-2530

E-mail: jjang@neuromed.com

Web: www.neuromed.com

Neuromed is a private biopharmaceutical company developing a new generation of safe and effective drugs to treat chronic and neuropathic pain. The company's drug development programs are designed around validated clinical targets associated with large unmet markets including cardiovascular disease and epilepsy, in addition to pain.

Neuromed is the first company to advance an oral N-type calcium channel blocker into human clinical trials. In March 2006, Neuromed and Merck & Co. signed a research collaboration and license agreement to research, develop and commercialize novel compounds for the treatment of pain and other neurological disorders, including Neuromed's lead compound NMED-160.

Company: Novelos Therapeutics, Inc.

Ticker Symbol & Exchange: NVLT:OTCBB

Investor Relations Contact: Stephen Lichaw

Phone: 212-856-5706

E-mail: slichaw@hcwainwright.com

Web: www.novelos.com

Novelos Therapeutics, Inc. is a biotechnology company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. NOV-002, the lead compound currently in Phase 3 development for lung cancer under a SPA and Fast Track, acts together with chemotherapy as a chemoprotectant and an immunomodulator. NOV-002 is also in Phase 2 development for chemotherapy-resistant ovarian cancer and early-stage breast cancer, and is in addition being developed for acute radiation injury. NOV-205 acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties. NOV-205 is in Phase 1b development for chronic hepatitis C non-responders. Both compounds have completed clinical trials in humans and have been approved for use in the Russian Federation where they were originally developed.

Company: NOXXON Pharma AG

Media Contact: Esther Hidebrandt

Investor Relations Contact: Dr. Sven Klussmann

Phone: +49-30-726-247-0

E-mail: ehildebrandt@noxxon.net

Web: www.noxxon.net

NOXXON Pharma AG is a drug discovery and development company with a validated proprietary technology platform to produce novel therapeutics. NOXXON's drugs, called Spiegelmers, are highly specific, biostable, next generation aptamers. NOXXON's business strategy is based on a three-branch approach:

-- Using its proprietary Spiegelmer technology, the Company builds its own pipeline of therapeutics for inflammatory diseases and angiogenic disorders.

-- NOXXON collaborates with pharmaceutical and biotechnology companies to create Spiegelmer therapeutics against targets of the partner's choosing.

-- NOXXON generates products for out-licensing at different research and development stages.

NOXXON's obesity product, Spiegelmer NOX-B11, was recently licensed to Pfizer Inc. for further development.

Company: Nucleonics, Inc.

Media Contact: Joan Kureczka, JKureczka@comcast.net

Investor Relations Contact: Robert Towarnicki

Phone: 267-518-0101

E-mail: rtowarnicki@nucleonicsinc.com

Web: www.nucleonicsinc.com

Nucleonics, Inc., founded in 2001, is a privately held, emerging biotechnology company focused on the development of novel RNA interference-based (RNAi) therapeutics for viral and other diseases. The company believes its proprietary technology and delivery systems for expressed interfering RNA (eiRNA) offers advantages over other RNA interference approaches in terms of safety and efficacy that will enable Nucleonics to become a leader in this emerging field. Nucleonics is initially focusing its efforts on the development of eiRNA-based therapeutics for chronic Hepatitis B and Hepatitis C infections and expects to file its first IND in Q4, 2006 for the treatment of chronic HBV. Pre-clinical programs targeting prostate and ovarian cancer were initiated in Q1 2006.

Company: NutraCea

Ticker Symbol & Exchange: NTRZ.OB OTC BB

Media Contact: Alisa Steinberg - Wolfe, Axelrod, Weinberger

Investor Relations Contact: Wolfe, Axelrod, Weinberger Associates

Steve Axelrod

Phone: 212-370-4500, Ext. 14

E-mail: steve@wolfeaxelrod.com

Web: www.wolfeaxelrod.com

NutraCea is the world leader in production and utilization of stabilized rice bran. NutraCea holds many patents for stabilized rice bran production technology and proprietary nutraceutical formulas ranging from arthritis, chronic bowel conditions, and effective diabetes control to cardiovascular disease treatment protocols. NutraCea's proprietary technology enables the creation of food and nutrition products to be unlocked from rice bran, normally a waste by-product of standard rice processing. Committed to helping the underfed, they're heavily involved in providing product and technology for developing countries through NutraCea's RiceAde feeding program.

Company: Oncolytics Biotech Inc.

Ticker Symbol & Exchange: TSX:ONC, NASDAQ:ONCY

Investor Relations Contact: Cathy Ward

Phone: 403-670-7377

E-mail: info@oncolyticsbiotech.com

Web: www.oncolyticsbiotech.com

Oncolytics Biotech Inc. was formed in 1998 to develop its proprietary product, REOLYSIN[R], as a potential therapeutic for a wide variety of human cancers.

Oncolytics has completed six clinical trials with REOLYSIN[R] in Canada, the U.K. and the U.S. and is currently conducting three Phase I or Phase I/II REOLYSIN[R] trials in the U.K. and the U.S. The company also has permission to commence a Phase II combination REOLYSIN[R] /radiation clinical trial in the U.K.

The current clinical program includes local or systemic delivery of REOLYSIN[R] as a monotherapy, and local delivery of REOLYSIN[R] in combination with radiation therapy for patients with advanced cancers.

Company: OncoMethylome Sciences

Ticker Symbol & Exchange: EN Brussels: ONCOB

Investor Relations Contact: Lucija Turcinov

Phone: +32-479-801-902

E-mail: Lucija.Turcinov@oncomethylome.com

Web: www.oncomethylome.com

OncoMethylome Sciences is a molecular diagnostics company developing gene methylation tests to assist physicians in effectively detecting and treating cancer. Specifically, the company's tests are designed to help the physician accurately detect cancer in early stages of cancer development, predict a patient's response to drug therapy, and predict the likelihood of cancer recurrence. OncoMethylome collaborates with leading international molecular oncology research centers, such as The Johns Hopkins University. The company's commercial partners include Veridex LLC (a Johnson & Johnson company) and Schering-Plough Corp. OncoMethylome's offices and laboratories are located in Durham (NC), Belgium, in the Netherlands.

Company: Opexa Therapeutics

Ticker Symbol & Exchange: NASDAQ:OPXA

Investor Relations Contact: Kim Sutton Golodetz / Lisa Lindberg

Phone: 212-838-3777

E-mail: kgolodetz@lhai.com / llindberg@lhai.com

Web: www.opexatherapeutics.com

Opexa Therapeutics develops and commercializes cell therapies to treat autoimmune diseases such as MS, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company's lead product, Tovaxin[TM], a T-cell therapy for multiple sclerosis is in Phase IIb trials. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is in preclinical development for type 1 diabetes.

Company: Oridion Systems Ltd.

Ticker Symbol & Exchange: ORIDN (SWX)

Investor Relations Contact: Elena Gerberg

Phone: +972-2-5899125

E-mail: elena.gerberg@oridion.com

Web: www.oridion.com

Oridion Systems Ltd. (www.oridion.com) develops proprietary medical devices and patient interfaces, based on its patented Microstream[R] technologies, for the enhancement of patient safety through the monitoring of the carbon dioxide (CO2) in a patient's breath, which is called capnography. These products are used in various clinical environments, including procedural sedation, pain management, operating rooms, critical care units, post-anesthesia care units, emergency medical services, transport, alternate care and other settings where patients' ventilation may be compromised and at risk. Oridion's growing team of partners includes Philips, Medtronic, Nellcor (Tyco), Datascope and Alaris. Oridion is the global leader in the rapidly growing capnography market.

Company: Orqis Medical Corporation

Media Contact: Brian McIntee, Director of Marketing

Investor Relations Contact: John M. Markovich, Chief Financial Officer

Phone: 949-707-5890 | 949-707-5894 (fax)

E-mail: info@orqis.com

Web: www.orqis.com

Orqis Medical Corporation is a privately held, clinical-stage medical device company seeking to redefine heart failure therapy by developing proprietary breakthrough products that prevent or reverse underlying disease progression and provide new treatment options to improve patient outcomes and quality of life. The percutaneous Cancion System for acutely decompensated chronic heart failure is currently being evaluated in the U.S. MOMENTUM Pivotal Trial. The implantable Exeleras System for chronic heart failure is in the final stages of pre-clinical testing and is planned for first clinical use in 2007. Visit www.orqis.com or www.momentumtrial.com for more details.

Company: Osiris Therapeutics, Inc.

Ticker Symbol & Exchange: OSIR

Investor Relations Contact: Lisa M. Rodemann

Phone: 410-522-5005, extension 610

E-mail: lrodemann@osiris.com Web: www.osiris.com

Osiris currently produces and sells OSTEOCEL[R], which is used in orthopedic surgery for the regeneration of bone. The Company has a strong drug development pipeline with five indications in active clinical trials. PROCHYMALTM is our stem cell drug for the treatment of inflammatory diseases including GVHD and Crohn's Disease. Currently, PROCHYMAL is in Phase III pivotal trials for GVHD and has been granted both Orphan Drug and Fast Track status by the FDA. The Company's pipeline of drug candidates under evaluation also includes CHONDROGENTM for regenerating cartilage in the knee, and PROVACELTM, for repairing heart tissue following a heart attack.

Company: Osteologix, Inc.

Ticker Symbol & Exchange: OTC BB:OLGX

Media Contact: Charles J. Casamento

Investor Relations Contact: Matthew M. Loar

Phone: 415-955-2720

E-mail: ml@osteologix.com

Web: www.osteologix.com

Osteologix develops innovative products for the treatment of important unmet medical needs in bone and cartilage diseases. The company's lead product, NB S101, is entering phase II clinical trials for the treatment of osteoporosis. It is believed that NB S101 both increases new bone formation and decreases bone resorption. No other product currently on the US market simultaneously increases bone formation and decreases bone resorption. The company is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding its pipeline and nurturing a unique company culture. Presentation: Monday 11/6, 3:55 p.m.

Company: Peplin Limited

Ticker Symbol & Exchange: ASX:PEP

Investor Relations Contact: Michael Aldridge

Phone: +61-7-3250-1200

E-mail: michael.aldridge@peplin.com

Web: www.peplin.com

Peplin Limited (a public company traded on ASX) is developing and commercializing cancer therapeutics. Peplin's lead compound (PEP005) is the first in a new class of investigational agents with a novel mechanism of action.

In May 2006 Peplin announced a US$30 million financing led by MPM Capital.

Peplin's lead programs are topical treatments (PEP005 Topical) for actinic keratosis (AK), a common pre-cancerous lesion and basal cell carcinoma (BCC), the most common form of skin cancer. PEP005 Topical is being developed as a cosmetically attractive non-surgical treatment for AK and BCC. Peplin believes the unique benefits of PEP005 Topical may include its short course of therapy and transient and favorable side effect profile. Peplin has completed four phase IIa trials in Australia and the U.S. For more information on Peplin, please visit www.peplin.com.

Company: Pharmacopeia

Ticker Symbol & Exchange: Nasdaq:PCOP

Investor Relations Contact: Amy Sharpless

Phone: 609-452-3643

E-mail: asharpless@pcop.com

Web: www.pharmacopeia.com

Pharmacopeia is committed to creating and delivering novel therapeutics to address significant medical needs. The Company is advancing multiple internal programs towards validation in clinical trials and possesses a later-stage portfolio of partnered programs.

Pharmacopeia's most advanced internal program is a dual-acting angiotensin (AT1) and endothelin (ETA) receptor antagonist (DARA) for hypertension and diabetic nephropathy that is currently in preclinical development. The Company is also advancing internal programs with potential efficacy in transplant rejection, psoriasis, rheumatoid arthritis, multiple sclerosis, Parkinson's disease, Alzheimer's disease and cancer. Additionally, Pharmacopeia currently has five partnered compounds in Phase I clinical trials and six partnered compounds in preclinical development.

Company: Pressure BioSciences, Inc.

Ticker Symbol & Exchange: PBIO

Investor Relations Contact: Richard Schumacher, CEO

Phone: 508-580-1800

E-mail: rschumacher@pressurebiosciences.com

Web: www.pressurebiosciences.com

Pressure BioSciences, Inc. (PBI) is a publicly traded, early-stage company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to rapidly, repeatedly, and safely control bio-molecular interactions. We currently hold 13 US/5 foreign patents covering multiple applications of PCT, including genomic and proteomic sample preparation, pathogen inactivation, enzyme control, immunodiagnostics, and protein purification. We market the PCT Sample Preparation System, an excellent tool for the extraction of DNA/RNA/proteins/small molecules from a variety of animal/plant/microbe/human cells and tissues.

Company: Prana Biotechnology Ltd.

Ticker Symbol & Exchange: NASDAQ:PRAN / ASX:PBT

Media Contact: Ivette Almeida

Investor Relations Contact: Kathy Price

Phone: +1-646-284-9400

E-mail: ialmeida@hfgcg.com / kprice@hfgcg.com

Web: www.pranabio.com

Prana Biotechnology's discoveries, emerging out of MGH at Harvard and the University of Melbourne in Australia, have lead to the development of MPAC's (Metal Protein Attenuating Compounds). MPAC's have shown great promise to treat a variety of neurodegenerative disorders. Prana's lead proprietary molecule, PBT2, is expected to commence Phase 2 clinical testing for Alzheimer's disease in the coming weeks. Clinical efficacy (Phase 2) for Alzheimer's was demonstrated earlier in a 'Proof of Principle' MPAC (clioquinol). Prana scientists are recognized global leaders in their fields, have published widely, and are the recipients of many industry awards for various contributions.

Company: ProMetic Life Sciences, Inc.

Ticker Symbol & Exchange: TSX:PLI

Investor Relations Contact: Kim Sutton Golodetz / Lisa Lindberg

Phone: 212-838-3777

E-mail: kgolodetz@lhai.com / llindberg@lhai.com

Web: www.prometic.com

ProMetic Life Sciences Inc. is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic LigandTM enabling technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of inflammation and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics.

Company: Pro-Pharmaceuticals, Inc. Ticker Symbol & Exchange: PRW: Amex

Investor Relations Contact: Tony Squeglia

Phone: 617.559.0033

E-mail: Squeglia@pro-pharmaceuticals.com Web: www.pro-pharmaceuticals.com

Pro-Pharmaceuticals is an early stage company engaged in the discovery, development and commercialization of carbohydrate-based therapeutic compounds for advanced treatment of cancer, liver, microbial, cardiovascular and inflammatory diseases, and viral infections. Initially, the product pipeline is principally focused on increasing the efficacy and decreasing the toxicity of approved chemotherapy drugs. DAVANAT[R], the Company's lead product candidate, is a complex carbohydrate drug that when given in combination with chemotherapeutic agents demonstrates reduced toxicity and increased efficacy by targeting the delivery of the chemotherapy to the tumor. The Company has completed a Phase l trial for all solid tumors and a Phase ll colorectal cancer trial and has conducted pre-clinical studies with its compounds in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin.

Company: Protherics Plc

Ticker Symbol & Exchange: PTI.L (LSE) and PTIL (NASDAQ)

Media Contact: Jonathan Birt, Financial Dynamics

Investor Relations Contact: Nick Staples

Phone: +44-207-246-9950

E-mail: nick.staples@protherics.com

Web: www.protherics.com

Protherics is an integrated biopharmaceutical company focused on the development, manufacture and marketing of specialist products for critical care and oncology. The Company's lead programmes are: CytoFab[TM], for severe sepsis, which following an encouraging phase 2b study has been out-licensed to AstraZeneca; Voraxaze[TM], an intervention treatment for when methotrexate blood levels remain dangerously high following high dose methotrexate cancer therapy, and approvals in the US and EU are anticipated in 2007. The majority of the Company's sales revenues are derived from two critical care products, CroFab[TM] (pit viper antivenom) and DigiFab[TM] (digoxin antidote) in the U.S.

Company: PURE Bioscience

Ticker Symbol & Exchange: (OTCBB:PURE)

Media Contact: Karen Kristopherson, Mentus

Investor Relations Contact: Terri MacInnis, Bibicoff & Associates

Phone: 619-596-8600, x101

E-mail: dsinger@purebio.com

Web: www.purebio.com

PURE Bioscience is an emerging specialty chemical and pharmaceutical company leveraging patented, patent-pending and EPA approved proprietary silver-based technology. PURE develops and markets products in the bioscience sector, providing non-toxic solutions to global health challenges. PURE's first product to market was Germ Control 24 hard surface disinfectant, true broad spectrum antibacterial, antifungal and antiviral. In addition to the licensing of its patented antimicrobial platform (SDC[TM]) by Ciba Specialty Chemicals for use in the household and personal care markets, PURE's SDC[TM] technology is being developed by internationally recognized drug development partner, Therapeutics, Inc., for pharmaceutical applications.

Company: Replidyne, Inc.

Ticker Symbol & Exchange: RDYN

Investor Relations Contact: Sabrina B. Oei

Phone: 303-996-5522

E-mail: soei@replidyne.com

Web: www.replidyne.com

Replidyne is a biopharmaceutical company focused on discovering, developing, in-licensing and commercializing innovative anti-infective products. Replidyne's lead product is faropenem medoxomil, a novel oral, community antibiotic, under development with partner Forest Laboratories. In October 2006, the FDA issued a non-approvable letter for faropenem requiring additional clinical studies and microbiologic evaluation in adult indications. The companies plan to meet with the FDA to define a clinical path moving forward. REP8839 is a topical anti-infective product candidate in Phase I development for the treatment of skin and wound infections, and the prevention of S. aureus infections, including MRSA infections, in hospital settings.

Company: Repligen Corporation

Ticker Symbol & Exchange: NASDAQ:RGEN

Investor Relations Contact: Laura Whitehouse, VP Market Development

Phone: 781-419-1812

E-mail: lwhitehouse@repligen.com

Web: www.repligen.com

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for diseases that affect the central nervous system. In addition, we currently market two commercial products Protein A and SecreFlo[R], which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from www.repligen.com.

Company: Response Biomedical Corporation

Ticker Symbol & Exchange: TSX-V:RBM, OTCBB:RPBIF

Media Contact: Bill Radvak, President and CEO

Investor Relations Contact: Rob Pilz, CFO and VP, Finance

Phone: 604-456-6010

E-mail: info@responsebio.com

Web: http://www.responsebio.com/index.asp

Response Biomedical develops, manufactures and markets rapid onsite diagnostic tests for use with its portable RAMP Platform for clinical and environmental applications. RAMP represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes.

The Company has recorded total revenues of C$1,122,365, including C$812,070 from product sales for the quarter ended June 30, 2006.

Response's Japanese partner, Shionogi & Co., Ltd., has launched the Company's rapid BNP Test for use in the prognosis and detection of congestive heart failure in Japan.

The Company is preparing to launch its RAMP NT-proBNP Test for use in the prognosis and detection of congestive heart failure in market. Further development milestones have been achieved on a rapid Staph A infectious disease test funded by 3M Medical division, which is preparing to commence clinical trials.

Company: Restore Medical, Inc.

Ticker Symbol & Exchange: NASDAQ:REST

Investor Relations Contact: Kim Sutton Goldetz / Lisa Lindberg

Phone: 212-838-3777

E-mail: kgolodetz@lhai.com / llindberg@lhai.com

Web: www.restoremedical.com

Restore Medical develops, manufactures and markets innovative medical devices to treat sleep-disordered breathing. The Company's proprietary Pillar[R] Palatal Implant System is the only implantable palatal device to treat snoring and mild-to-moderate obstructive sleep apnea to be approved by the U.S. Food and Drug Administration and Health Canada, and to have received the CE Mark for sale in the European Union. The Pillar Palatal Implant System is sold throughout the U.S. and Canada, and in various countries in Asia Pacific, Europe, South America and the Middle East.

Company: Savient Pharmaceuticals, Inc.

Ticker Symbol & Exchange: NASDAQ:SVNT

Investor Relations Contact: Kim Sutton Golodetz / Anne Marie Fields

Phone: 212-838-3777

E-mail: kgolodetz@lhai.com / afields@lhai.com

Web: www.savientpharma.com

Savient Pharmaceuticals is a biopharmaceutical company engaged in developing and marketing pharmaceutical products that target unmet medical needs in both niche and broader markets. The Company's lead product development candidate, Puricase[R] (PEG-uricase) for treatment failure gout, has reported positive Phase 1 and 2 clinical data; Phase 3 clinical studies began in May 2006. Savient's experienced management team is committed to advancing its pipeline and expanding its product portfolio by in-licensing late-stage compounds and exploring co-promotion and co-development opportunities that fit the Company's expertise in biopharmaceuticals with an initial focus in rheumatology.

Company: Senesco Technologies, Inc.

Ticker Symbol & Exchange: AMEX:SNT

Investor Relations Contact: Kim Sutton Golodetz / Anne Marie Fields

Phone: 212-838-3777

E-mail: kgolodetz@lhai.com / afields@lhai.com

Web: www.senesco.com

Senesco has initiated preclinical research to trigger or delay apoptosis to determine if its technology is applicable in human medicine. Accelerating apoptosis may have applications to the development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as glaucoma, ischemia and arthritis, among others. In addition to its human health research programs, the Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress for flowers, fruits and vegetables.

Company: Sinclair Pharma plc

Ticker Symbol & Exchange: AIM: SPH

Investor Relations Contact: Zoe McDougall

Phone: +44 (0) 1483-610-400

E-mail: investorrelations@sinclairpharma.com

Web: www.sinclairpharma.com

Sinclair Pharma plc is an international specialty pharmaceutical company, with a growing sales and marketing operation that is already present in France, Italy, the U.K., Spain and Portugal, and a complementary marketing partner network that spans 60 countries. Sinclair focuses in niche therapeutic areas with a current focus on products in dermatology and oral health.

Sinclair's goal is to become a sustainability profitable international pharmaceutical company, focusing in niche therapeutic areas, with a direct commercial presence in the key commercial markets.

To achieve this, Sinclair has a 'buy and build' strategy. To optimize our commercial efficiency, we are building a sales and marketing operation that focuses on niche audiences. Sinclair will access other important audiences for its products through relationships with commercial partners.

Company: Sirtris Pharmaceuticals

Media Contact: Kathryn Morris, 845-635-9828

Investor Relations Contact: Michelle Dipp

E-mail: mdipp@sirtrispharma.com

Web: www.sirtrispharma.com

Sirtris Pharmaceuticals[TM] is a biopharmaceutical company developing novel therapeutics that modulate sirtuins. Sirtris has the dominant sirtuin intellectual property estate and know-how with a comprehensive suite of reagents, proprietary assays, transgenic animal models and biomarkers. Sirtris is building a robust pipeline of therapeutics for diseases of aging in the areas of metabolic and mitochondrial disorders. Sirtris was founded by Rich Aldrich, Richard Pops, Paul Schimmel, David Sinclair and Christoph Westphal.

Company: Solianis Monitoring AG

Investor Relations Contact: Mario Stark

Phone: +41-44-306-80-40

E-mail: mario.stark@solianis.com

Web: www.solianis.com

Solianis is a Swiss Medical device company developing a non-invasive, continuous glucose monitor for patients with diabetes. It has developed a multi-sensor concept based on impendance spectroscopy that is designed to address the difficulty of tracking glucose changes in everyday use. In a clinical-experimental trial with healthy human subjects the expanded sensor system was tested successfully. Solianis is currently running an external clinical study including patients with diabetes. The results look promising and indicate that a reliable tracking of glucose changes in daily life is possible. The next milestones are to complete the external clinical study, integrate the sensor system into a functional model and further develop the algorithm for the calculation of glucose changes. Solianis owns an impressive patent portfolio, including a new patent for the multi-sensor concept.

Company: Somanta Pharmaceuticals, Inc.

Ticker Symbol & Exchange: OTCBB:SMPM

Investor Relations Contact: Don Markley

Phone: 310-691-7100

E-mail: dmarkley@lhai.com

Web: www.somanta.com

Somanta Pharmaceuticals, Inc. ("Somanta") is a specialty oncology company with particular focus on in-licensing anti-cancer agents with substantial clinical data supporting safety and efficacy. To date, the Company has successfully in-licensed the rights to five products, each with a different mode of action and targeting eleven different cancer types. Presentation: 11/06/06 @ 4:15 p.m.

Company: Spectranetics Corporation

Ticker Symbol & Exchange: Nasdaq: SPNC

Investor Relations Contact: Don Markley, Lippert/Heilshorn

Phone: 310-691-7100

E-mail: dmarkley@lhai.com

Web: www.spectranetics.com

Spectranetics is a medical device company that develops, manufactures and markets single-use medical devices used in minimally invasive surgical procedures within the cardiovascular system in conjunction with its proprietary excimer laser system. Excimer laser technology delivers relatively cool ultraviolet energy to ablate or remove arterial blockages including plaque, calcium and thrombus. We believe our CVX-300[R] excimer laser is the only system approved in the United States, Europe, Japan, and Canada for use in multiple, minimally invasive cardiovascular procedures. These procedures include atherectomy, which is a procedure to remove arterial blockages in the peripheral or coronary vasculature, and the removal of infected, defective or abandoned cardiac lead wires from patients with pacemakers or implantable cardiac defibrillators, or ICDs. Presentation: 11/07/06 @ 10:15 a.m.

Company: SyntheMed, Inc.

Ticker Symbol & Exchange: SYMD.OB

Media Contact: Francesca T. DeVellis

Investor Relations Contact: Tara Spiess; 914-921-5900; Spiess@biotechirpr.com

Web: http://www.synthemed.com

SyntheMed is a biomaterials company engaged in the development and commercialization of anti-adhesion and drug delivery products. SyntheMed's REPEL-CV[R], a bioresorbable adhesion barrier intended for use in cardiac surgery, recently received CE Mark approval in the EU and has been launched in the EU and certain Southeast Asian markets through a network of independent distributors. In September 2006, the company released positive efficacy data from the REPEL-CV multi-center pivotal clinical trial. The company intends to submit a Premarket Approval application to the FDA that, if approved, would allow for REPEL-CV to be marketed in the U.S. SyntheMed plans to launch the product in the U.S. in mid 2007 through a direct sales force. The worldwide market for cardiac anti-adhesion products is estimated to be in excess of $300 million annually.

Company: Synthetic Blood Internationl

Ticker Symbol & Exchange: OTCBB: SYBD

Investor Relations Contact: Brandi Floberg

Phone: 310-691-7100

E-mail: bfloberg@lhai.com

Web: www.sybd.com

Synthetic Blood International develops innovative pharmaceuticals and medical devices with oxygen therapeutic and continuous substrate monitoring technologies. The Company's products are based on perfluorocarbon (PFC) and biosensor technologies. Synthetic Blood's lead product candidate, Oxycyte[TM], is being developed as a safe and effective alternative to transfused blood for use in surgical and similar medical situations, and as a therapeutic oxygen carrier. In August 2006, Synthetic Blood completed treatment in its Phase IIa study to evaluate Oxycyte's ability to increase brain oxygen tension and favorably affect other brain chemistries that impact clinical outcome in traumatic brain injury patients, as well as further assess the safety of Oxycyte when given by intravenous infusion. Oxycyte administration increased oxygen tension over baseline in all eight evaluable trial patients. The Company expects to announce preliminary data analysis from this trial in the 2006 fourth quarter. Other products in the Company's pipeline include Fluorovent[TM], a liquid ventilator providing oxygen exchange and surfactant fluid for facilitating the treatment of lung conditions, and a biosensor implant product that uses an enzyme process for measuring the glucose level in the blood stream. Synthetic Blood International's presentation is Nov. 7 at 9:55 a.m. ET.

Company: Tercica, Inc.

Ticker Symbol & Exchange: Nasdaq:TRCA

Media Contact: Kathleen Rinehart, Dir. Public Relations

Investor Relations Contact: Fredrik Wiklund, IR and Corp. Comm.

Phone: 650-624-4900

E-mail: fredrik.wiklund@tercica.com

Web: www.tercica.com

Tercica, Inc. is a biopharmaceutical company focused on the development and commercialization of products to improve endocrine health. The company's first product, Increlex[TM] (mecasermin [rDNA origin] injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the long-term treatment of severe Primary IGFD. Presentation: 11/07/06 @ 3:55 p.m.

Company: TorreyPines Therapeutics, Inc.

Ticker Symbol & Exchange: Nasdaq:TPTX

Media Contact: Evelyn Graham, Chief Operating Officer

Investor Relations Contact: Craig Johnson, Chief Financial Officer

Phone: 858-623-5665

E-mail: info@torreypinestherapeutics.com

Web: www.torreypinestherapeutics.com

TorreyPines Therapeutics, Inc. is a biopharmaceutical company that discovers and develops small molecule drugs to treat diseases and disorders of the central nervous system. Led by an accomplished management team, TorreyPines is leveraging novel drug targets and technologies to potentially deliver new CNS therapies for migraine; chronic pain, including neuropathic pain; and cognitive disorders, including Alzheimer's disease and schizophrenia. The company's pipeline includes eight product candidates, five of which are clinical stage. In October, TorreyPines initiated a Phase IIb study in acute migraine for tezampanel, its lead product candidate.

Company: TRACON Pharmaceuticals

Investor Relations Contact: Delia Valdovinos

Phone: 858-550-0780, ext. 232

E-mail: dvaldovinos@traconpharma.com

Web: www.traconpharma.com

TRACON is an emerging biotechnology company focused on identifying, developing and commercializing targeted therapies for cancer and angiogenesis. TRACON's management team will leverage their experience developing the current generation of targeted agents, to advance the development of the next generation of targeted therapeutics. TRACON has in-licensed product candidates that possess advantageous safety profiles that will allow them to combine easily with existing therapies, including a monoclonal antibody that prevents the activation of the essential angiogenic target, a small molecule that reverses resistance to chemotherapy and a liposome embedded with an apoptotic agent that will also be loaded with chemotherapy.

Company: TRANSGENE

Ticker Symbol & Exchange: XPAR:TNG FP

Media Contact: Capital MS&L, shaun.brown@capitalmsl.com

Investor Relations Contact: Philippe Poncet

Phone: + 33-3-88-27-91-02

E-mail: poncet@transgene.fr

Web: www.transgene.fr

Transgene is a France-based biopharmaceutical company dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases. The company has three compounds in Phase II trials and one compound in Phase I study. Transgene has bio-manufacturing capacities for the production of viral-based vectors (adenovirus and vaccinia virus) and technologies available for out-licensing.

By developing expertise in applied research, clinical and production capabilities (2800 sq. meter GMP production facility) while maintaining broad intellectual property of over 200 patent families, Transgene is uniquely poised to advance cancer and infectious diseases therapies through both in-house and partnered development.

Company: Transport Pharmaceuticals

Investor Relations Contact: Dennis Goldberg, Ph.D., President and C.E.O.

Phone: 508-739-8112

E-mail: dgoldberg@transportpharma.com

Web: www.transportpharma.com

Transport is revolutionizing the treatment of dermal diseases by bringing together cutting edge electronics, drug formulation and materials science to develop novel drug/device combination products. This unique combination of technologies can improve the delivery of topically applied drugs and the utility of potent systemically delivered drugs whose uses are limited by bioavailability, toxicity or side effect concerns.

SoloVir[TM], Transport's lead product for the treatment of herpes labialis, or cold sores is based on the combination of iontophoresis, a technology employing a low-voltage electrical charge to locally deliver larger amounts of medications through the skin, and a proprietary acyclovir formulation that has been optimized for electrokinetic delivery. The Company has developed a reusable, microprocessor driven control unit that fits on one finger, in combination with a single-use, unit-dose drug cartridge. This combination drug/device system allows patients to accurately self-administer the drug with the confidence that they will receive the proper dose, directly to the site where the drug is needed, each time the system is used.

Transport operates in a highly efficient manner through the use of contract vendors to perform all activities other than ideation and project management. Transport manages the design, manufacturing, pre-clinical and clinical research activities of its vendors with a highly interactive, team-oriented philosophy.

Company: Trinity Biotech plc

Ticker Symbol & Exchange: (NASDAQ:TRIB, ISE:TRIB.I)

Media Contact: Mr Brendan Farrell & Mr Rory Nealon

Investor Relations Contact: Mr Rory Nealon

Phone: 353-1-2769800

E-mail: rory.nealon@trinitybiotech.com

Web: www.trinitybiotech.com

Trinity Biotech develops, acquires, manufactures and markets over 500 diagnostic products for the point-of-care and clinical laboratory segments of the diagnostic market. The broad line of test kits are used to detect infectious diseases, sexually transmitted diseases, blood coagulation disorders, and autoimmune diseases. Trinity Biotech sells worldwide in over 80 countries through its own salesforce and a network of international distributors and strategic partners. For further information, please see the Company's website: www.trinitybiotech.com.

Company: Vasogen

Ticker Symbol & Exchange: vsgn - Nasdaq Global Market

Investor Relations Contact: Glenn Neumann

Phone: 905-817-2004

E-mail: gneumann@vasogen.com

Web: www.vasogen.com

Vasogen is focused on the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease. Vasogen's Celacade technology is in late-stage development for the treatment of chronic heart failure. The recently completed phase III ACCLAIM trial assessed the impact of Celacade on reducing the risk of mortality and morbidity in patients with Class II-IV systolic heart failure. Vasogen is also developing a new class of drugs for the treatment of neuro-inflammatory and neuro-vascular disorders. VP025, which is entering phase II clinical development, is the lead product candidate from this new class of drugs.

Company: Viral Genetics, Inc.

Ticker Symbol & Exchange: VRAL.OB

Media Contact: Kirsten Ayars, 805-452-7909

Investor Relations Contact: Evan Pondel, 310-279-5973

Phone: 626-334-5310

Web: www.viralgenetics.com

Viral Genetics, Inc. is a biotechnology company that discovers and develops immune-based therapies for HIV and AIDS using its thymus nuclear protein compound. This compound may have other potential applications for other infectious, autoimmune, and immunological deficiency diseases that the company intends to study in the future. Viral Genetics believes that VGV-1 represents a significant and unique approach to treating HIV due to the apparently novel mechanism, low toxicity profile, simple dosing regimen, and short-course of treatment.

Company: VIVUS, Inc.

Ticker Symbol & Exchange: NASDAQ:VVUS

Media Contact: Tim Brons - Vida Communication, 415-675-7402

Investor Relations Contact: Stephanie Diaz - Vida Communication, 415-675-7401

Phone: 650-934-5200

E-mail: ir@vivus.com

Web: www.vivus.com

VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of next-generation therapeutics addressing obesity and sexual health. Our pipeline includes: Qnexa[TM], for which a Phase 2 study has been completed for the treatment of obesity; Testosterone MDTS[R], for which a Phase 2 study has been completed for the treatment of Hypoactive Sexual Desire Disorder (HSDD); EvaMist[TM], for which a Phase 3 study has been completed and an NDA submitted for the treatment of menopausal symptoms; and avanafil, for which a Phase 2 study has been completed for the treatment of erectile dysfunction (ED).

Company: Xanthus Pharmaceuticals, Inc.

Media Contact: Kari Watson, MacDougall Bio Medical

Investor Relations Contact: Lisa Terry, Corporate Communications

Phone: 617-252-6105

E-mail: lisa.terry@xanthus.com

Web: www.xanthus.com

Xanthus is a biopharmaceutical company focused on the discovery, development, acquisition and commercialization of small-molecule therapeutics for the treatment of cancer and autoimmune disorders. We believe that our scientific depth and broad clinical development expertise provide us with the capability to discover novel therapies, as well as identify, license or acquire products that address cancer and autoimmune disorders not adequately treated with existing therapies.

Company: Xencor, Inc.

Investor Relations Contact: Kim Richards

Phone: 619-849-5377

E-mail: krichards@pnlifesciences.com

Web: www.xencor.com

Xencor discovers and develops novel biotherapeutics and has established a diversified preclinical pipeline focused on oncology and autoimmune diseases, with its first Phase I trial initiation expected in late 2006. The leading candidates in its portfolio are engineered antibodies and proteins with superior therapeutic properties that target clinically and commercially validated drug targets. Application of Xencor's protein design platforms has now generated a portfolio of new biotherapeutics with broad utility. Xencor's protein optimization capability has enabled multiple product and technology collaborations that both validate Xencor's design capabilities and create a virtual pipeline to complement its internal drug pipeline.

Company: XenoPort, Inc.

Ticker Symbol & Exchange: Nasdaq:XNPT

Investor Relations Contact: Jackie Cossmon

Phone: 408-616-7295

E-mail: Jackie.Cossmon@XenoPort.com

Web: www.XenoPort.com

XenoPort, Inc. a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates for the potential treatment of central nervous system (CNS) disorders. It also has a product candidate for the potential treatment of gastroesophageal reflux disease, or GERD. XenoPort's drug discovery efforts focus on utilizing the body's natural nutrient transporter mechanisms to improve the therapeutic benefits of drugs. The most advanced product candidate is being developed for the potential treatment of restless legs syndrome, or RLS, and the management of neuropathic pain. The second product candidate is being evaluated for the potential treatment of GERD.

Company: XOMA Ltd.

Ticker Symbol & Exchange: Nasdaq:XOMA

Investor Relations Contact: Mr. Paul Goodson

Phone: 510-204-7270

E-mail: goodson@xoma.com

Web: xoma.com

XOMA is a leader in the discovery, development and manufacture of therapeutic monoclonal antibodies (mAbs) with a therapeutic focus that includes cancer and immune diseases. XOMA's mAb platform includes leading commercial antibody display phage libraries, hybridoma, Human Engineering[TM], affinity maturation technologies, and a fully integrated product development infrastructure, including cell line and process development, preclinical and clinical functions, and manufacturing. XOMA's pipeline includes both proprietary products and collaborative programs. XOMA receives royalties for RAPTIVA[R] and LUCENTIS[TM]. Other strategic collaborations include Novartis AG (formerly Chiron Corporation), Schering-Plough Corporation and Lexicon Genetics, Inc.

Company: York Pharma plc

Ticker Symbol & Exchange: YRK - London

Investor Relations Contact: Annabel Entress, Northbank Communication

Phone: +44(0)20-3008-7550

E-mail: YorkPharma@Northbankcommunications.com

Web: http://www.YorkPharma.com

York Pharma is a specialty pharmaceutical company aimed at discovering, acquiring, developing and commercialising novel and superior prescription dermatological products.

The Company's portfolio consists of six 1st in class products addressing the important anti-fungal, psoriasis, eczema and acne markets that collectively make up 75% of the $10.4bn global prescription dermatology market.

Abasol, the Company's lead antifungal product offers features and benefits that York believes will give it a distinct competitive advantage in a $2.4bn market. The Company is preparing for its first commercial launch of the product in 1st Half 2007.

With the novel treatments Vampex and Sabarep progressing through clinical development for psoriasis and eczema respectively and preclincal projects progressing for acne and malignant melanoma, York is poised to make a significant impact in dermatology.

Company: ZIOPHARM Oncology, Inc.

Ticker Symbol & Exchange: NASDAQ:ZIOP

Media Contact: Tina Posterli, 917-322-2565

Investor Relations Contact: Suzanne McKenna

Phone: 646-214-0703

E-mail: smckena@ziopharm.com

Web: www.ziopharm.com

ZIOPHARM Oncology is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 3, 2006
Words:16032
Previous Article:IncrediMail to Exhibit at 2006 ad:tech New York Conference.
Next Article:Microsoft Solutions to Drive Healthcare Technology in Massachusetts.
Topics:


Related Articles
Callisto's Drug Development Achievements to be Spotlighted at Rodman & Renshaw Techvest Healthcare Investor Conference; Company to Present Latest...
Rodman & Renshaw 3rd Annual Global Healthcare Conference May 15-16, 2006, Monte Carlo, Monaco.
Rodman & Renshaw 3rd Annual Global Healthcare Conference Will Take Place on May 15-16, 2006, in Monte Carlo, Monaco; Join Us for One of the Premier...
Rodman & Renshaw 3rd Annual Global Healthcare Conference Will Take Place on May 15-16, 2006 in Monte Carlo, Monaco. Join Us for One of the Premier...
Rodman & Renshaw 3rd Annual Global Healthcare Conference, May 15-16, 2006; The Le Meridien Beach Plaza Hotel -- at the Sea Club 22, Avenue Princesse...
Callisto to Present Leading Anti-Cancer Drug Candidates at Rodman & Renshaw Healthcare Conference in Monaco; CEO Dr. Gary Jacob to Discuss Latest...
Rodman & Renshaw 3rd Annual Global Healthcare Conference Will Take Place on May 15-16, 2006, in Monte Carlo, Monaco; Join Us for One of the Premier...
Rodman & Renshaw 8th Annual Healthcare Conference Will Take Place on November 6-8, 2006 at the New York Palace Hotel in New York; Join Us for One of...
Rodman & Renshaw Healthcare Conference 2006 Additional Presenter Profile.
Rodman & Renshaw Global Healthcare Conference 2007 Presenter Profiles.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters